scispace - formally typeset
E

Elisabetta Bezzon

Publications -  13
Citations -  442

Elisabetta Bezzon is an academic researcher. The author has contributed to research in topics: Mammography & Digital mammography. The author has an hindex of 6, co-authored 12 publications receiving 402 citations.

Papers
More filters
Journal ArticleDOI

Digital breast tomosynthesis versus digital mammography: a clinical performance study

TL;DR: Clinical performance of tomosynthesis in one view at the same total dose as standard screen-film mammography is not inferior to digital mammography in two views.
Journal ArticleDOI

Performance comparison of single-view digital breast tomosynthesis plus single-view digital mammography with two-view digital mammography.

TL;DR: Breast tomosynthesis (DBT) has emerged as a valuable adjunct to mammography (MX) in terms of ROC curve area, sensitivity and specificity and was superior to two-view MX in recognising benign lesions.
Journal ArticleDOI

Combination of one-view digital breast tomosynthesis with one-view digital mammography versus standard two-view digital mammography: per lesion analysis

TL;DR: This study shows that readers’ capabilities in detecting and characterizing breast lesions are improved by combining single- view digital breast tomosynthesis and single-view mammography compared to two-view digital mammography.
Journal ArticleDOI

First-Line sunitinib in patients with renal cell carcinoma (RCC) in von Hippel-Lindau (VHL) disease: clinical outcome and patterns of radiological response.

TL;DR: Sunitinib may achieve a fairly good disease control in VHL patients, andRadiological responses may be obtained not only in renal tumors but also in synchronous VHL-related lesions, especially pancreatic solid nodules whose exact nature cannot be ruled out without invasive biopsy.
Journal ArticleDOI

Immunotherapy and urothelial carcinoma: An overview and future prospectives

TL;DR: Strong evidence supports the use of CPIs after failure of Cisplatin-based chemotherapy, although no predictive parameter is available so far, and neoadjuvant trials with CPIs and trials combining two CPIs are promising and will further expand theUse of immunotherapy.